US 11,891,401 B2
Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide
Yudong Cao, Changshu (CN); Siyi Jiang, Shanghai (CN); Hongyong Kim, Changshu (CN); Andreas Kordikowski, Binningen (CH); Irene Xia, Pudong (CN); Bo Yu, Changshu (CN); Jing Zhang, Changshu (CN); and Yi Zhao, Changshu (CN)
Assigned to NOVARTIS AG, Basel (CH)
Appl. No. 17/281,528
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Oct. 8, 2019, PCT No. PCT/IB2019/058535
§ 371(c)(1), (2) Date Mar. 30, 2021,
PCT Pub. No. WO2020/075046, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. PCT/CN2018/109415 (WO), filed on Oct. 9, 2018.
Prior Publication US 2022/0041604 A1, Feb. 10, 2022
Int. Cl. C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07C 57/15 (2006.01); A61P 33/02 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 33/02 (2018.01); C07C 57/15 (2013.01); C07B 2200/13 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A co-crystal comprising N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)[2,4]triazolo[1,5- a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide and fumaric acid; wherein said co-crystal is characterized by:
(i) an X-ray powder diffraction pattern comprising three or more 2θ peaks selected from 24.7°±0.2°, 23.9°±0.2°, 16.0°±0.2° (2θ) and 13.4°±0.2° (2θ);
(ii) an X-ray powder diffraction pattern comprising three or more three or more 2θ peaks selected from 27.6°±0.2°, 14.8°±0.2°, 9.8°±0.2°, 11.3°±0.2°, 24.6°±0.2°, 25.0°±0.2° and 26.5°±0.2° (2θ); or
(iii) an X-ray powder diffraction pattern comprising three or more 2θ peaks selected from 13.5°±0.2°, 3.8°±0.2°, 17.2°±0.2°and 26.6°±0.2 (2θ);
when measured with a CuKα radiation at a wavelength of 0.15 nm at room temperature.